The candidate for the COVID-19 vaccine from China- BBIBP-CorV is safe. Experts were expecting that the vaccine will completely inactivate the SARS-CoV-2 virus. This vaccine elicits an antibody response. This was from a recent report published by The Lancet. An earlier clinical trial reported the same type of results for a different vaccine which is also based on the inactivated whole virus. But that vaccine was only trialed on people below age 60 years.
More About The COVID-19 Vaccine :
The Lancet Infectious Diseases journal’s latest study reported included participants in the range of 18 to 80 years. They recorded antibody responses to all recipients in the report. Participants who were 60 plus age was slower to respond, taking around 42 days before antibodies were detected. However, the response was around 28 days for participants aged 18 to 59.
“Safety of older people is a major concern of a successful COVID-19 vaccine. This is because of the most risks involved for older age from Coronavirus.” This was a statement of study author Xiaoming Yang, Beijing Institute of Biological Products Company Limited in China.
As we know at this age, the immune system gets weakened so the vaccine is a bit less effective sometimes.
“It is hence motivating to see that BBIBP-CorV induces responses of antibody in patients aged 60 plus. We believe this justifies further investigation,” Yang further added.
How Does The Process work?
The researchers developed stocks of the virus in the lab using cell lines. They then activate them using a chemical called beta-propionolactone.
BBIBP-CorV contains a killed virus mixed with various other components. The component is aluminum hydroxide, which boosts immune responses. Phase one of their study was designed to find the optimal quantity to take for a safe dose of BBIBP-CorV.
The process of trials started with a group of 96 healthy volunteers aged between 18 and 59 years. Another group had participants aged 60 to 80 years. Within each group, they tested the vaccine at three different dose levels, from day zero-day 28.
A subgroup within each age group containing 24 participants from each group, were given two doses of a placebo vaccine. In the first phase, a total of 144 participants received the vaccine, and 48 received the placebo.
In the second phase of the study, they asked participants to report any adverse effects for the first seven days after each vaccination. The research team verified these effects.
“No serious adverse events were reported within 28 days of the final vaccination. There were no instances of clinically significant changes in organ functions detected in laboratory tests in any of the groups.” The authors wrote this in the report.